Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, announced that it has secured $17 million in a subsequent financing round. Terms of the investment were not disclosed.
The company noted that Domain Associates, LLC led the financing round, and AgeChem Venture Fund LP joined previous investors Thomas, McNerney & Partners, LLC, Forward Ventures and Isis Pharmaceuticals, Inc. (ISIS)
San Diego-based Altair said it has planned to utilize the funding to complete phase 2a trials for its inhaled AIR645 product and advance research and development in new target programs.
Joel Martin, President and CEO of Altair Therapeutics, said, "We are thrilled to have Domain Associates and Agechem Venture Fund join our investor syndicate,"
For comments and feedback: editorial@rttnews.com